DEA Confirms HHC Is Federally Illegal and Assigns Unique Drug Code
The DEA has formally declared that synthetic cannabinoid HHC is a Schedule I controlled substance and does not qualify as legal hemp, assigning it a unique drug code for enforcement
Key Points
- 1The DEA clarified that HHC is federally illegal and classified as a Schedule I substance
- 2HHC, though derived from hemp components, is considered synthetic and not covered by the 2018 Farm Bill
- 3The DEA assigned HHC a specific drug code to formalize its regulatory status
- 4A new rule will allow the DEA to set quotas for HHC production by registered manufacturers
- 5Federal appeals courts have sometimes challenged the DEA's interpretation of hemp legality under the Farm Bill
The U.S. Drug Enforcement Administration (DEA) has clarified that hexahydrocannabinol (HHC), a synthetic cannabinoid derived from cannabis, is federally classified as a Schedule I controlled substance. In a move set to be published in the Federal Register, the DEA is assigning HHC its own specific drug code, reinforcing its illegal status under the Controlled Substances Act (CSA). HHC, which can be synthesized from cannabidiol (CBD) and is sometimes used to enhance cannabis products low in delta-9 THC, has psychoactive properties similar to THC, raising concerns among regulators
According to the DEA, the 2018 Farm Bill's legalization of hemp and its derivatives does not extend to synthetic cannabinoids like HHC. "Only tetrahydrocannabinols in or derived from the cannabis plant—not synthetic tetrahydrocannabinols—are excluded from control as 'tetrahydrocannabinols in hemp,'" the agency stated. This clarification means that even if HHC is produced from hemp-derived CBD, it remains a controlled substance due to its synthetic nature
The agency's stance echoes a 2023 letter from Terrance Boos, chief of DEA’s Drug and Chemical Evaluation Section, who noted that HHC "does not occur naturally in the cannabis plant and can only be obtained synthetically, and therefore does not fall under the definition of hemp." The new Federal Register notice, signed by DEA Administrator Terrance Cole, further specifies, "This action, as an administrative matter, establishes a separate, specific listing for hexahydrocannabinol in schedule I of the CSA and assigns a DEA drug code for this substance." This will allow the DEA to set quotas for registered manufacturers of HHC, formalizing oversight
While the DEA's position is backed by the U.S. Department of Health and Human Services, some federal appeals courts have previously challenged the agency's interpretation of the Farm Bill's scope. Additionally, a recent international move placed HHC under Schedule II of the United Nations Convention on Psychotropic Substances, though the U.S. abstained from that vote. Retailers and manufacturers must also prepare for further changes this November, when new federal rules will restrict legal hemp products to those containing no more than 0.4 milligrams of total THC per container, unless Congress intervenes
From the OG Lab newsroom perspective, this clear federal prohibition of HHC tightens the regulatory landscape for synthetic cannabinoids and signals heightened scrutiny for products that blur the line between hemp and controlled substances. Industry stakeholders should closely monitor evolving federal and international policies, as further regulatory adjustments could impact product offerings and compliance requirements across the U.S. cannabis market
